{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'e-diary instruction and review and set up. The e-diary should be turned to Part 2 at the', 'conclusion of these assessments, prior to randomization and study drug dispensing for', 'Part 2.', 'After completion of the above bulleted items at the conclusion of the visit, Part 2 study drug may', 'be dispensed from the IXRS and accountability performed. The first dose of study drug in Part 2', 'may be administered (if timing coincides with typical dosing time, see Section 9.3.2). Study drug', 'in Part 2, if not given at the visit, should be taken the day of the visit.', 'During the Part 2 dosing period, investigators will contact subjects to discuss details of all', 'angioedema events recorded in the e-diary within approximately 2 business days of the end of', 'the angioedema event. Moreover, any noncompliance will warrant contact with the subject.', '10.3.4.', 'Part 2', '10.3.4.1. Week 26 Visit', 'The Week 26 visit (Day 183 2 days) will consist of monitoring liver function tests only (ALT,', 'AST, GGT, total and direct bilirubin, ALP); urine and additional tubes of blood may be required', 'to accommodate reflex testing for abnormal GGT, AST, or ALT (see Table 5). If preferred by', 'the subject and clinical site, laboratory values may be drawn and resulted locally, with results', 'entered into the eCRF.', 'During the Part 2 dosing period, investigators will contact subjects to discuss details of all', 'angioedema events recorded in the e-diary within approximately 2 business days of the end of', 'the angioedema event. Moreover, any noncompliance will warrant contact with the subject.', '10.3.4.2. Week 28, 32, 36, 48, and 52 Visits', 'Subjects will return to the clinic during Week 28 (Day 197 2 days), Week 32', '(Day 225 2 days), Week 36 (Day 253 2 days), Week 48 (Day 337 7 days), and Week 52', '(Day 365 2 days).', 'Subjects do not need to withhold any doses on clinic days or take a dose in the clinic, unless the', \"clinic visit falls during the subject's normal time of dosing.\", 'The following assessments will be performed:', 'Administration of EQ-5D-5L (1-2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Where possible, the questionnaires should be completed by the', 'subject prior to other assessments to prevent influencing subject perceptions.', 'Subject weight', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG (single assessments)', 'Abbreviated physical examination (targeted to new signs and symptoms)', 'Blood collection for clinical chemistry, hematology, and coagulation, troponin I and', 'troponin T, NGAL, and CK-MB', 'PK concentration and PD plasma samples', '69']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT, and urine pregnancy test for all female subjects of childbearing potential', 'Review of concomitant medications and AEs', 'Review of angioedema events and dosing e-diary completion and study drug', 'compliance. The e-diary should be turned to Follow-up at the conclusion of the', 'Week 52 visit.', 'Study drug accountability and dispensing.', 'During the Part 2 dosing period, investigators will contact subjects to discuss details of all', 'angioedema events recorded in the e-diary within approximately 2 business days of the end of', 'the angioedema event. Moreover, any noncompliance will warrant contact with the subject.', '10.3.4.3. Week 40 and 44 Phone Calls', 'The investigator (or designee) must call and talk to the subject once during Weeks 40 and 44;', 'alternative forms of interactive communication such as returned email and cellular text', 'correspondence are acceptable. During all calls, the investigator (or designee) will assess the', \"subject's overall wellbeing, discuss compliance (if applicable), proper recording of angioedema\", 'event details (if applicable), or any usability issues with the e-diary. The phone call may be', 'omitted if the subject records an angioedema event as the investigator must call and confirm or', 'reject the angioedema event.', '10.3.5.', 'Part 3', '10.3.5.1. Week 60, 72, 84, 96, and 104 Visits', 'Subjects will return to the clinic during Week 60 (Day 421 6 days), Week 72', '(Day 505 6 days), Week 84 (Day 589 6 days), Week 96 (Day 673 6 days), and Week 104', '(Day 729 7 days).', 'Subjects do not need to withhold any doses on clinic days or take a dose in the clinic, unless the', \"clinic visit occurs during the subject's normal time of dosing.\", 'The following assessments will be performed:', 'Administration of EQ-5D-5L (1 or 2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Where possible, the questionnaires should be completed by the', 'subject prior to other assessments to prevent influencing subject perceptions.', 'Subject weight (adolescent subjects will also have height measured at Weeks 48 and', '96)', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG (single assessments)', 'Abbreviated physical examination (targeted to new signs and symptoms)', 'Blood collection for clinical chemistry, hematology, and coagulation, troponin I and', 'troponin T, NGAL, and CK-MB', '70']\n\n###\n\n", "completion": "END"}